Abstract

Clear cell renal cell carcinoma (ccRCC) is the most-prominent tumor type of kidney cancers. Resistance of renal cell carcinoma (RCC) against tumor therapy is often owing to apoptosis resistance, e.g., by overexpression of anti-apoptotic proteins. However, little is known about the role of the apoptosis inhibitor c-FLIP and its potential impact on death receptor-induced apoptosis in ccRCC cells. In this study, we demonstrate that c-FLIP is crucial for resistance against CD95L-induced apoptosis in four ccRCC cell lines. Strikingly, downregulation of c-FLIP expression by short hairpin RNA (shRNA)interference led to spontaneous caspase activation and apoptotic cell death. Of note, knockdown of all c-FLIP splice variants was required to induce apoptosis. Stimulation of ccRCC cells with CD95L induced NF-κB and MAP kinase survival pathways as revealed by phosphorylation of RelA/p65 and Erk1/2. Interestingly, CD95L surface expression was high in all cell lines analyzed, and CD95 but not TNF-R1 clustered at cell contact sites. Downstream of CD95, inhibition of the NF-κB pathway led to spontaneous cell death. Surprisingly, knockdown experiments revealed that c-FLIP inhibits NF-κB activation in the context of CD95 signaling. Thus, c-FLIP inhibits apoptosis and dampens NF-κB downstream of CD95 but allows NF-κB activation to a level sufficient for ccRCC cell survival. In summary, we demonstrate a complex CD95-FLIP-NF-κB-signaling circuit, in which CD95-CD95L interactions mediate a paracrine survival signal in ccRCC cells with c-FLIP and NF-κB both being required for inhibiting cell death and ensuring survival. Our findings might lead to novel therapeutic approaches of RCC by circumventing apoptosis resistance.

Highlights

  • Renal cell carcinoma (RCC) accounts for 3.8% of malignancies of the adult and over 90% of kidney tumors[1]

  • The apoptosis inhibitor c-FLIP was expressed by all four cell lines analyzed, with c-FLIPL expression being higher than expression of the short splice variants c-FLIPS and c-FLIPR in clearCa-2 and -3 cell lines (Fig. 1b)

  • We focused on the role of c-FLIP-mediated CD95L resistance in RCC

Read more

Summary

Introduction

Renal cell carcinoma (RCC) accounts for 3.8% of malignancies of the adult and over 90% of kidney tumors[1]. RCC is a cancer of the proximal renal tubular epithelium and the collecting tubular epithelium and comprises a variety of malignancies that differ in histology and on the molecular level[1,2,3]. One particular type of RCC, the clear cell RCC (ccRCC), often exhibits mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and in PBRM1, a component of the PBAF chromatin-remodeling complex[4]. Another main characteristic of RCC is the Resistance to apoptosis is a hallmark of cancer cells and can lead to tumor formation[7]. The protein Fas-associated protein with death domain (FADD) binds to CD95 and acts as recruitment platform

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call